Steve Slovick
Managing Director
Steve is a Managing Director at STS Capital Partners with more than 35 years of leadership experience in the global life sciences and pharmaceutical sectors. A seasoned M&A professional and former industry executive, he spent over a decade with leading companies, gaining deep expertise in sales, marketing, lifecycle management, and corporate strategy. He has completed or advised on more than 30 transactions, many exceeding $1 billion in value, including company sales, product divestitures, and strategic acquisitions. Having also founded, scaled, and successfully sold two businesses, including one in a nine-figure transaction, Steve brings a distinctive dual perspective as both a business owner and sell-side advisor, enabling him to help clients realize maximum value from their exits.
Throughout his career, Steve has specialized in business development, valuation, commercialization strategy, and deal execution across the life sciences industry. He has led commercial and financial analyses to determine asset value, developed exit and positioning strategies for innovators, and guided leadership teams through every stage of the M&A process, from market preparation to negotiation and post-acquisition integration. His firsthand understanding of how major industry players evaluate and acquire assets gives his clients a strategic advantage when engaging with potential buyers.
In the early 2000s, he became Senior Vice President at Cambridge Pharma Consultancy, soon helping to divest the company to IMS Health. After successful integration, he became a Founder, President, and Partner at PriceSpective, a global consultancy specializing in pricing, market access, and value strategy for the biopharmaceutical industry. Under his leadership, PriceSpective grew into a globally recognized firm and was acquired in 2012 by ICON plc. Steve played an integral role in structuring and executing that transaction, realizing strong strategic and financial synergies between the two organizations.
Building on that success, Steve founded Jupiter Life Science Consulting in 2015, serving as CEO and Managing Partner. Jupiter became a trusted advisor to leading pharma, biotech, and medical device companies worldwide, providing commercial and market access strategies to address complex pricing, reimbursement, and launch challenges. In 2022, Jupiter was acquired by Red Nucleus, where Steve continued as President of Market Access & Commercial Strategy (MACS), leading global integration and ongoing client delivery.
Steve’s track record of both creating and realizing enterprise value as an entrepreneur, strategic consultant, and M&A advisor positions him as a trusted partner to life science founders and executives seeking to prepare their companies for sale and achieve Extraordinary Exits™.
Steve holds dual BS degrees in Marketing and International Business from the University of Colorado Boulder, as well as a Master of Business Administration from the Pepperdine Graziadio Business School.
INSIGHTS & PERSPECTIVES FROM INDUSTRY EXPERTS
Actionable insights, strategic thinking, and expert advice to help you plan, prepare, and succeed in your exit journey.
Featured
In the News
GIVE MORE & GET WEALTHIER DOING IT
June 1, 2026
Featured
Podcasts & Videos
The M&A Truths No One Tells Founders
May 29, 2026
In a recent episode of the InOrganic Podcast, hosts Ayelet Shipley and Christian Hassold sit down with Brenda Jacobsen, STS Managing Director, to explore what it really takes to prepare for a successf…
Featured
Thought Leadership
Why Discipline Matters in an Exit
May 15, 2026
For many entrepreneurs, selling a business represents the culmination of years of dedication, risk-taking, and persistence. It is not only an emotional milestone but also a significant financial event…
Podcasts & Videos
The Extraordinary Exit: Paths & Journeys That Make a Difference
May 4, 2026
In a recent episode of Conversation with Legends, host Stephen Christie sits down with Andy Harris, STS President of North American Strategies and Managing Director, to explore what it really takes to…
In the News
Winning an Exit
April 30, 2026
Thought Leadership
The Exit Blind Spot
April 22, 2026
Selling your business is more than a transaction; it’s one of the most consequential decisions of your life as an owner. It shapes your financial future, defines your legacy, and determines the fate o…